Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/16/2017
Start Date:January 15, 2011

Use our guide to learn which trials are right for you!

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole,
letrozole, or exemestane with or without chemotherapy work in treating patients with breast
cancer that has spread from where it began in the breast to surrounding normal tissue
(invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using
tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor
cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast
cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether giving
tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination
chemotherapy in treating patients with breast cancer.

PRIMARY OBJECTIVES:

I. To determine the effect of chemotherapy in patients with node positive breast cancer who
do not have high recurrence scores (RS) by Oncotype DX.

SECONDARY OBJECTIVES:

I. To compare overall survival (OS), distant disease-free survival (DDFS) and local
disease-free interval (LDFI) by receipt of chemotherapy or not and its interaction with RS.

II. To compare the toxicity across the treatment arms. III. To perform other assays or tests
(in particular the prediction analysis of microarray [PAM50] risk of relapse score), as they
are developed and validated that measure potential benefit of chemotherapy and compare them
to Oncotype DX.

IV. To determine the impact of management with Oncotype DX on patient-reported anxiety
(co-primary Health-Related Quality of Life [HRQL] outcome) prior to screening, after
disclosure of test results, and during the randomized trial.

V. To determine the impact of Oncotype DX on the initial management cost of node-positive,
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative
breast cancer.

VI. To compare patient-reported utilities (e.g., quality of life [QOL]) for those randomized
to chemotherapy versus no chemotherapy.

VII. Using modeling and DFS information from the trial, to estimate the cost-effectiveness of
management with Oncotype DX vs usual care.

VIII. To determine the role of other assays (e.g., PAM50) as predictors of DFS, DDFS, and
LDFI for patients randomized to chemotherapy versus no chemotherapy.

IX. To determine the impact of treatment with chemotherapy versus no chemotherapy on
patient-reported fatigue and cognitive concerns (secondary HRQL outcomes).

X. To determine the impact of management with Oncotype DX on patient-reported decision
conflict, perceptions regarding Oncotype DX testing, and survivor concerns prior to
screening, after disclosure of test results, and during the randomized trial (secondary HRQL
outcomes).

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive a protocol-approved chemotherapy regimen based on the patient and/or
physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy
comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane),
or both for 5-10 years in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate,
an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the
absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year,
every 6 months for 4 years, and then yearly for 15 years.

Inclusion Criteria:

- Patients must have a histologically confirmed diagnosis of node positive (1-3 nodes)
invasive breast carcinoma with positive estrogen and/or progesterone receptor status,
and negative HER-2 status; estrogen and progesterone receptor positivity must be
assessed according to American Society of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guidelines as either estrogen receptor (ER) or progesterone
receptor (PR) >= 1% positive nuclear staining; HER-2 test result negativity must be
assessed as per ASCO/CAP 2013 guidelines using immunohistochemistry (IHC), in situ
hybridization (ISH) or both; HER-2 is negative if a single test (or all tests)
performed in a tumor specimen show: a) IHC negative (0 or 1+) or b) ISH negative using
single probe or dual probe (average HER-2 copy number < 4.0 signals per cell by single
probe or HER-2/CEP ration < 2.0 with an average copy number < 4.0 signals per cell by
dual probe); if HER-2 IHC is 2+, evaluation for gene amplification (ISH) must be
performed and the ISH must be negative; ISH is not required if IHC is 0 or 1+; HER-2
equivocal is not eligible

- Patients with multifocal, multicentric and synchronous bilateral breast cancers are
allowed

- Multifocal disease is defined as more than one invasive cancer < 2 cm from the
largest lesion within the same breast quadrant; (NOTE: the Oncotype DX testing
must be completed on the largest lesion)

- Multicentric disease is defined as more than one invasive cancer >= 2 cm from the
largest lesion within the same breast quadrant or more than one lesion in
different quadrants (NOTE: Oncotype DX testing should be completed on all tumors
and the determination for eligibility should be made on the highest recurrence
score)

- Synchronous bilateral disease is defined as invasive breast cancer with positive
lymph nodes (axillary or intramammary) in at least one breast, diagnosed within
30 days of each other; (NOTE: the Oncotype DX testing should be completed on both
tumors and the tumor with the highest recurrence score should be used)

- Patients will have undergone axillary staging by sentinel node biopsy or axillary
lymph nodes dissection (ALND); patients must have at least one, but no more than three
known positive lymph nodes (pN1a, pN1b or pN1c); patients with micrometastases as the
only nodal involvement (pN1mi) are not eligible; patients with positive sentinel node
are not required to undergo full axillary lymph node dissection; this is at the
discretion of the treating physician; axillary node evaluation is to be performed per
the standard of care at each institution

- Patients must not have inflammatory breast cancer and must not have metastatic disease

- Patients with a prior diagnosis of contralateral ductal carcinoma in situ (DCIS) are
eligible if they underwent a mastectomy or lumpectomy with whole breast radiation;
prior partial breast irradiation, including brachytherapy, is not allowed; patients
with a prior diagnosis of ipsilateral DCIS or invasive breast cancer who received
radiation to that breast are not eligible

- Patients must have had either breast-conserving surgery with planned radiation therapy
or total mastectomy (with or without planned postmastectomy radiation); patients must
have clear margins from both invasive breast cancer and DCIS (as per local
institutional guidelines); lobular carcinoma in situ (LCIS) at the margins is allowed

- Registration of patients who have not yet undergone Oncotype DX screening must occur
no later than 56 days after definitive surgery; (for all patients, Step 2 Registration
must occur within 84 days after definitive surgery); if the Oncotype DX Breast Cancer
Assay has not been performed, patients must be willing to submit tissue samples for
testing to determine the Recurrence Score value; a representative block or unstained
sections from the representative block are sent directly to Genomic Health for
Oncotype DX Breast Cancer Assay which will be performed according to the standard
commercial process

- If the Oncotype DX Recurrence Score is already known and is 25 or less, the
patient must be registered to Step 2 immediately following Step 1 registration;
if the Oncotype DX Recurrence Score is already known and is greater than 25, the
patient is ineligible

- Patients must have a complete history and physical examination within 28 days prior to
registration

- Patients must have a performance status of 0-2 by Zubrod criteria

- Patients must be able to receive taxane and/or anthracycline based chemotherapy

- Patients must not have begun chemotherapy or endocrine therapy for their breast cancer
prior to registration

- Patients must not require chronic treatment with systemic steroids (inhaled steroids
are allowed) or other immunosuppressive agents

- Patients must not have received an aromatase inhibitor (AI) or a selective estrogen
receptor modulator (SERM) such as tamoxifen or raloxifene within 5 years prior to
registration

- Patients must not be pregnant or nursing; women of reproductive potential must have
agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- No other prior malignancy is allowed except for adequately treated basal cell (or
squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the
patient has been disease-free for 5 years

- The Quality of Life and Economic Substudy is permanently closed to accrual effective
12/1/12; patients who consented to QOL prior to 12/1/12 should continue to complete
QOL forms per their expectation report; patients who are able to complete a
questionnaire in English must be offered the opportunity to participate in the Quality
of Life and Economic Substudy; (The Quality of Life and Economic Substudy is available
to U.S. INSTITUTIONS ONLY); patients who are not able to complete a questionnaire in
English are registered to S1007 without participating in the Quality of Life and
Economic Substudy

- Patients who consent to participate in the Quality of Life and Economic Substudy
and who do not yet know the results of their Oncotype DX screening must agree to
complete the S1007 Health-Related Quality of Life Questionnaire: Enrollment
between 14 days prior to and 7 days after Step 1 Registration

- Patients who consent to participate in the Quality of Life and Economic Substudy
and who do already know their Oncotype DX Recurrence Score (and it is 25 or less)
will proceed to Step 2 Registration without completing the S1007 Health-Related
Quality of Life Questionnaire Enrollment Form (but will complete the S1007
Health-Related Quality of Life Questionnaire: Randomized Study Form)

- Patients or their legally authorized representative must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines; for Step 1 registration of
patients who have not yet submitted specimens for the Oncotype DX Breast Cancer Assay,
the appropriate consent form is the Step 1 Consent Form; for both Step 1 and Step 2
registration of patients whose Recurrence Score is already known and is 25 or less,
the appropriate consent form is the Step 2 Consent Form

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system

- STEP 2 REGISTRATION

- Recurrence score (RS) by Oncotype DX must be =< 25

- Step 2 Registration must take place within 84 days after definitive surgery; patients
must not have begun chemotherapy or endocrine therapy for their breast cancer prior to
randomization

- Patients randomized to either arm may also co-enroll in phase III trials that compare
local therapies, or compare systemic therapies (such as chemotherapy, if randomized to
Arm I of S1007)

- The Quality of Life and Economic Substudy is permanently closed to accrual effective
12/1/12; patients at U.S. INSTITUTIONS who consent to participate in the Quality of
Life and Economic Substudy must agree to complete the S1007 Health-Related Quality of
Life Questionnaire: Randomized Study Form after Recurrence Score results and
randomized treatment status are known but before treatment has been initiated

- Patients or their legally authorized representative must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines; for all patients the
appropriate consent form for this registration is the Step 2 Consent
We found this trial at
1437
sites
Anaheim, California 92806
Principal Investigator: Han A. Koh
Phone: 626-564-3455
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Zoneddy R. Dayao
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
?
mi
from
Augusta, ME
Click here to add this to my saved trials
8600 Old Georgetown Road
Bethesda, Maryland 20814
301-896-3100
Principal Investigator: Antonio C. Wolff
Phone: 410-955-8804
Suburban Hospital Suburban Hospital is a community-based, not-for-profit hospital serving Montgomery County and the surrounding...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Nancy U. Lin
Phone: 877-442-3324
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Nancy U. Lin
Phone: 877-442-3324
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 501-622-2100
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Ellis G. Levine
Phone: 877-275-7724
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Farrah B. Khan
Phone: 802-656-4101
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Patrick M. Dillon
Phone: 434-243-6322
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Joanne E. Mortimer
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Karen C. Daily
Phone: 352-273-8675
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Jupiter, Florida 33458
?
mi
from
Jupiter, FL
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Sunil Nagpal
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
701 Doctors Dr
Kinston, North Carolina 28504
(252) 559-2200
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
?
mi
from
Kinston, NC
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 805-474-9143
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Monica M. Mita
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
777 Hemlock Street
Macon, Georgia 31201
(478) 633-1000
Principal Investigator: Frederick M. Schnell
Phone: 478-633-1226
Medical Center of Central Georgia Navicent Health is a designated Level I Trauma Center and...
?
mi
from
Macon, GA
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Jane E. Carleton
Phone: 516-734-8954
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
305 1st Avenue # Dazian 7
New York, New York 10003
(212) 420-2806
Principal Investigator: Paula Klein
Phone: 212-367-1729
Beth Israel Med Ctr The physicians and staff of Mount Sinai Beth Israel's Heart Institute...
?
mi
from
New York, NY
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Kathleen A. Kemmer
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Maria Constantinou
Phone: 401-444-1488
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Harry D. Bear
Phone: 888-823-5923
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Jonathan W. Friedberg
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Kate I. Lathrop
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Julie R. Gralow
Phone: 800-422-6237
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Julie R. Gralow
Phone: 800-422-6237
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: Amy K. Krie
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
(509) 228-1000
Principal Investigator: Julie R. Gralow
Phone: 800-422-6237
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
?
mi
from
Spokane, WA
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
?
mi
from
Yakima, WA
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Abbotsford, British Columbia
Principal Investigator: Dorothy L. Uhlman
Phone: 604-851-4710
?
mi
from
Abbotsford,
Click here to add this to my saved trials
Aberdeen, South Dakota 57401
Principal Investigator: Amy K. Krie
Phone: 888-634-7268
?
mi
from
Aberdeen, SD
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
?
mi
from
Adrian, MI
Click here to add this to my saved trials
818 Riverside Ave.
Adrian, Michigan 49221
(517) 265-0900
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
?
mi
from
Adrian, MI
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Jennifer E. Payne
Phone: 330-615-4132
?
mi
from
Akron, OH
Click here to add this to my saved trials
1 Akron General Ave
Akron, Ohio 44307
(330) 344-6000
Akron General Medical Center It
?
mi
from
Akron, OH
Click here to add this to my saved trials
Alamosa, Colorado 81101
Principal Investigator: Anthony D. Elias
Phone: 720-848-0650
?
mi
from
Alamosa, CO
Click here to add this to my saved trials
Albany, Georgia 31701
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
?
mi
from
Albany, GA
Click here to add this to my saved trials
Albemarle, North Carolina 28002
Principal Investigator: Geetha Vallabhaneni
Phone: 404-778-1868
?
mi
from
Albemarle, NC
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
Principal Investigator: Zoneddy R. Dayao
Phone: 505-925-0366
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Alexandria, Louisiana 71301
Principal Investigator: John T. Cole
Phone: 504-842-3708
?
mi
from
Alexandria, LA
Click here to add this to my saved trials
Alexandria, Minnesota 56308
?
mi
from
Alexandria, MN
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Alton, Illinois 62002
?
mi
from
Alton, IL
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Brian T. Pruitt
Phone: 806-212-1985
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
Principal Investigator: Derrick S. Haslem
Phone: 801-408-1347
?
mi
from
American Fork, UT
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Ames, IA
Click here to add this to my saved trials
1111 Duff Ave
Ames, Iowa 50010
(866) 972-5477
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anacortes, Washington 98221
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Keith S. Lanier
Phone: 503-215-2614
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anderson, South Carolina 29621
?
mi
from
Anderson, SC
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: John E. Doster
Phone: 864-512-1000
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 208-367-7954
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Anne F. Schott
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Anniston, AL
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 877-405-6866
?
mi
from
Antigo, WI
Click here to add this to my saved trials
?
mi
from
Antioch, CA
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Louis Fehrenbacher
Phone: 626-564-3455
?
mi
from
Antioch, CA
Click here to add this to my saved trials
Appleton, Wisconsin 54913
Principal Investigator: William A. Conkright
Phone: 920-749-1171
?
mi
from
Appleton, WI
Click here to add this to my saved trials
?
mi
from
Appleton, WI
Click here to add this to my saved trials
?
mi
from
Ardmore, OK
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
(336) 625-5151
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0821
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
?
mi
from
Asheboro, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28816
Principal Investigator: Cameron B. Harkness
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Ashland, Kentucky 41101
Principal Investigator: David K. Goebel
Phone: 888-823-5923
?
mi
from
Ashland, KY
Click here to add this to my saved trials
Atlanta, Georgia 30303
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
5665 Peachtree Dunwoody Rd NE
Atlanta, Georgia 30342
(678) 843-7001
Saint Joseph's Hospital of Atlanta Founded by the Sisters of Mercy in 1880, Saint Joseph
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1968 Peachtree Rd NW
Atlanta, Georgia 30309
(404) 605-5000
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Kelly A. May
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Attleboro, Massachusetts 02703
Principal Investigator: Jonathan B. Croopnick
Phone: 508-236-7059
?
mi
from
Attleboro, MA
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 907-458-5380
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-1663
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials